REPEATED USE OF BRAF AND MEK INHIBITORS IN METASTATIC MELANOMA PATIENTS AFTER PROFRESSION ON BRAF AND МЕК INHIBITORS. LITERATURE REVIEW AND CLINICAL OBSERVATION
oleh: I. V. Samoylenko, Y. A. Zhulikov, L. V. Demidov
| Format: | Article |
|---|---|
| Diterbitkan: | Remedium Group LLC 2017-11-01 |
Deskripsi
Development of new effective drugs for therapy of metastatic melanoma (BRAF/MEK inhibitors, PD1/CTLA4 blockers) requires additional studies of the optimal sequence of their use. But in many cases the duration of the effect of these medicinal products is limited by time even in their sequential use. This literature review considers a possibility of repeated indication of BRAF/ MEK inhibitors after progression on them in various clinical settings. The potential use of such approach is illustrated by two own clinical observations.